Comprehensive clinical reference guide to the landmark 2026 NICE guideline update — expanded GLP-1 RA indications, new treatment algorithms, and precision prescribing recommendations for UK clinicians.
The most significant update to the NICE T2DM guideline in a decade, with major expansions to GLP-1 RA access and first-line treatment strategies.
GLP-1 RAs now recommended across three major new categories: established atherosclerotic CVD, early-onset T2DM (diagnosed <40 years), and those living with obesity — regardless of HbA1c threshold.
Major ExpansionSGLT-2 inhibitors are now recommended for ALL adults with T2DM at diagnosis, not just those with CVD or CKD. Modified-release metformin now recognised as standard treatment to improve tolerability.
Paradigm ShiftMedicines introduced one at a time: start metformin → add SGLT-2i at max tolerated dose → add GLP-1 RA or tirzepatide when SGLT-2i is optimised. Prevents polypharmacy overwhelm and improves tolerability.
New ProtocolPatients diagnosed with T2DM before age 40 face higher lifetime CV and renal risk. Guideline now mandates consideration of earlier escalation to GLP-1 RA or tirzepatide for this high-risk group.
New PathwayNICE explicitly states: do NOT offer both a GLP-1 RA (or tirzepatide) AND a DPP-4 inhibitor together. Overlapping mechanism of action makes this combination clinically redundant and not cost-effective.
ContraindicationOzempic (sc semaglutide up to 1mg weekly) is the preferred GLP-1 RA for patients with atherosclerotic CVD, with the strongest evidence base for MACE reduction in the SUSTAIN-6 and SELECT trials.
Preferred AgentUnderstanding the pleiotropic effects that underpin the expanded NICE indications.
Tirzepatide (Mounjaro®) acts as a dual GIP + GLP-1 receptor agonist. GIP potentiates insulin secretion, reduces glucagonoma-related nausea, and enhances fat metabolism. This synergy explains its superior efficacy over pure GLP-1 RAs.
Decision algorithm for initiating and escalating GLP-1 receptor agonist therapy in adults with type 2 diabetes.
NICE 2026 creates distinct pathways for high-risk subgroups. GLP-1 RA should be considered for all populations below.
Established coronary artery disease, peripheral arterial disease, ischaemic stroke, or TIA caused by blocked arteries.
Higher lifetime risk of cardiovascular and renal complications; aggressive early treatment indicated.
Weight loss benefit of GLP-1 RA is now recognised as a sufficient indication independent of glycaemic targets.
GLP-1 RA can be used alongside SGLT-2i for renoprotection in patients with T2DM and CKD.
Tirzepatide and GLP-1 RAs with HF benefit now recommended in symptomatic HFpEF with T2DM and obesity.
GLP-1 RAs with demonstrated MASH benefit are now specifically recommended for this rapidly growing comorbidity.
At time of publication (February 2026), NICE NG28 specifies the following GLP-1 receptor agonists for T2DM.
Landmark cardiovascular outcomes trials and organ-protection studies underpinning the expanded GLP-1 RA indications.
Structured monitoring schedule for patients initiating GLP-1 receptor agonist therapy in primary or secondary care.
Modified approaches for complex clinical scenarios encountered in UK clinical practice.
eGFR >30: All GLP-1 RAs may be used. No dose adjustment required for liraglutide, dulaglutide, or semaglutide sc based on eGFR alone.
eGFR 20–30: SGLT-2i + DPP-4i preferred combination. GLP-1 RA initiation and continuation still possible — NICE now permits this in advanced CKD per 2026 update.
Dialysis/ESKD: GLP-1 RAs generally avoided. Specialist nephrology input required. Insulin management preferred.
Note: Semaglutide has the strongest renal protection data (FLOW trial: 24% ↓ kidney failure risk).
Pregnancy: GLP-1 RAs are CONTRAINDICATED in pregnancy. Stop at least 2 months (semaglutide) before planned conception due to long half-life. Switch to insulin.
Breastfeeding: Avoid all GLP-1 RAs. Insufficient safety data available.
Tirzepatide + Oral Contraceptives: Tirzepatide reduces absorption of oral contraceptives. Add barrier method for 4 weeks after initiation AND after each dose increase. Non-oral contraceptives (implant, patch, ring) are unaffected. Copper IUD: most effective emergency contraception if needed.
Oral HRT: British Menopause Society 2025 cautions potential reduced progestogen absorption with tirzepatide — consider transdermal or vaginal preparations.
Frailty: Treatment goals shift from aggressive glycaemic control to symptom management and avoiding hypoglycaemia.
HbA1c Targets: Relaxed to 58–64 mmol/mol (7.5–8%) in frail patients. Avoid tight control to prevent hypoglycaemia, falls, and cognitive effects.
Preferred agents in frailty: DPP-4 inhibitors (sitagliptin, alogliptin) — minimal side effects, no hypoglycaemia, renal dose-adjustable.
GLP-1 RAs in frailty: Use with caution. Risk of nausea, anorexia, and weight loss that may cause undernutrition. Monitor BMI carefully — stop if underweight (<18.5 kg/m²).
GLP-1 RA may be continued in frail patients IF being used specifically for cardiovascular protection with ongoing monitoring.
SUSTAIN-6 Signal: Semaglutide showed a higher rate of retinopathy complications vs placebo in SUSTAIN-6, particularly with rapid HbA1c reduction in those with pre-existing retinopathy.
Tirzepatide: Not studied in patients with non-proliferative DR requiring acute therapy, proliferative DR, or diabetic macular oedema. Use with caution and appropriate monitoring.
Best Practice: Always ensure up-to-date retinal screen before initiating GLP-1 RA. If pre-existing moderate-to-severe NPDR or proliferative DR — seek ophthalmology input before commencing. Avoid rapid HbA1c reduction (>2% within 3 months) in high-risk retinopathy patients.
Comprehensive safety reference for GLP-1 receptor agonist prescribing and monitoring in clinical practice.
The underpinning philosophy driving the NICE NG28 February 2026 update to T2DM management.
Move away from "one-size-fits-all." Individualise HbA1c targets, drug choices, and treatment escalation based on comorbidities, age, patient preference, and clinical context.
Prioritise agents with proven cardiorenal outcome data. SGLT-2i and GLP-1 RAs are preferred over agents with glycaemic-only benefits in high-risk patients.
Address under-prescribing of SGLT-2i and GLP-1 RAs to women, older adults, and Black patients. Actively monitor prescribing equity across all demographic groups.
Introduce medicines one at a time to identify tolerability and efficacy of each agent. Reduces polypharmacy confusion and improves patient adherence and safety.
When drugs are clinically equivalent, choose the least expensive. Generic dapagliflozin saves NHS £560m — reinvest savings into education and community support.
Now includes periodontitis screening — bidirectional relationship between T2DM and gum disease is recognised. Full cardiometabolic review at every annual diabetes check.
CGM significantly expanded for T2DM on insulin, particularly for recurrent/severe hypoglycaemia. IS-CGM recommended at diagnosis and any time thereafter on insulin therapy.
Annual screening for anxiety and fear of hypoglycaemia now recommended. Referral to behavioural therapist if diabetes distress not addressed in consultation.